For the past eight months, Innolife Pharma, Inc. (OTC: INNP) has been active in conversations regarding the formation of a joint venture partnership. The company is now writing the final terms that have been submitted on all key issues. This could very well lead to the company’s first product acquisition, and through this intense period of establishing a joint venture the company is hopeful more progress will come in the near future. On Monday the company saw a rise of 252.94% in their stock.
There are two main areas that management is watching closely. One is the awarding of valuable rights to Innolife Pharma for a leading industry product. The brand is popularly known for innovation and consistency spanning a period of two decades. Since the brand has already been established, it can be launched into a new target market, creating the largest market of this type on a global scale.
The second area is that of solidifying a joint venture with a partner of great quality and experience. The company’s goal is to combine their market access capabilities and distribution techniques with the knowledge, leadership and existing contracts of a potential joint venture partner. Updates will be released by the company as they become available. The company has anticipated the potential size of the target market at $20 billion.
Innolife Pharma, Inc. holds a unique, evidence-based and clinically proven centralized pain model approach that focuses on reversing the endorphin, serotonin and other neurotransmitter depletion found in chronic pain sufferers. The result is significant relief from long-lasting pain, insomnia, and depression without the use of narcotics, surgery, or ongoing supplementation.
Let us hear your thoughts below:
